ATE454626T1 - Fluoreszenzpolarisationsassay - Google Patents

Fluoreszenzpolarisationsassay

Info

Publication number
ATE454626T1
ATE454626T1 AT05725848T AT05725848T ATE454626T1 AT E454626 T1 ATE454626 T1 AT E454626T1 AT 05725848 T AT05725848 T AT 05725848T AT 05725848 T AT05725848 T AT 05725848T AT E454626 T1 ATE454626 T1 AT E454626T1
Authority
AT
Austria
Prior art keywords
rage
systems
methods
fluorescence polarization
polarization assay
Prior art date
Application number
AT05725848T
Other languages
English (en)
Inventor
Adnan Mjalli
Jeffrey Webster
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Application granted granted Critical
Publication of ATE454626T1 publication Critical patent/ATE454626T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05725848T 2004-03-18 2005-03-18 Fluoreszenzpolarisationsassay ATE454626T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55418304P 2004-03-18 2004-03-18
PCT/US2005/009005 WO2005089454A2 (en) 2004-03-18 2005-03-18 Fluorescence polarization assay

Publications (1)

Publication Number Publication Date
ATE454626T1 true ATE454626T1 (de) 2010-01-15

Family

ID=34994362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05725848T ATE454626T1 (de) 2004-03-18 2005-03-18 Fluoreszenzpolarisationsassay

Country Status (13)

Country Link
US (1) US20070154954A1 (de)
EP (1) EP1730526B1 (de)
JP (1) JP4607950B2 (de)
CN (1) CN1938591B (de)
AT (1) ATE454626T1 (de)
AU (1) AU2005223660B2 (de)
CA (1) CA2559723C (de)
DE (1) DE602005018751D1 (de)
ES (1) ES2337699T3 (de)
IL (1) IL177915A0 (de)
MX (1) MXPA06010659A (de)
NZ (1) NZ549847A (de)
WO (1) WO2005089454A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102175846A (zh) * 2010-12-24 2011-09-07 江南大学 一种双酚a的荧光偏振免疫分析检测方法
CN102879587B (zh) * 2011-10-21 2014-09-17 成都医学院 一种脂联素受体配基及激动剂的筛选方法
CN109453401B (zh) * 2018-12-15 2019-12-10 江苏大学附属医院 一种18f-sfb-cml的用途及检测动脉粥样硬化的方法
CN109432453B (zh) * 2018-12-15 2019-11-15 江苏大学附属医院 一种靶向性分子探针在血管钙化检测产品中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873313A (en) * 1985-01-18 1989-10-10 Beckman Research Institute Of City Of Hope Specific hybridoma cell line and monocolonal antibodies produced from such specific hybridoma cell line and method of using such monoclonal antibodies to detect carcinoembryonic antigens
JPH0643159A (ja) * 1991-02-20 1994-02-18 Toyobo Co Ltd 固定化dnaまたはrnaを用いるdnaまたはrna断片の測定方法
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
CA2250067A1 (en) * 1996-04-18 1997-10-23 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
JP3647587B2 (ja) * 1997-01-20 2005-05-11 シスメックス株式会社 免疫測定法
JP3255293B2 (ja) * 1997-09-05 2002-02-12 松下電器産業株式会社 蛍光偏光法
CN1560609A (zh) * 1998-03-06 2005-01-05 ŵ����÷�����޹�˾ 荧光偏振筛选法
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
US7423177B2 (en) * 2001-03-05 2008-09-09 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation
AU2002245590B2 (en) * 2001-03-05 2006-06-29 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
EP1415997A4 (de) * 2001-07-19 2005-03-30 Mitsubishi Pharma Corp Polypeptide, die bei der signalübertragung des advanced-glycation-end-product-rezeptors eine rolle spielen
EP2324830A1 (de) * 2002-03-05 2011-05-25 TransTech Pharma Inc. Verfahren zur Herstellung von einem monozylische Azolderivat das die Interaktion von Liganden mit Rage hemmt
ATE437884T1 (de) * 2003-05-29 2009-08-15 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen

Also Published As

Publication number Publication date
JP4607950B2 (ja) 2011-01-05
CA2559723A1 (en) 2005-09-29
ES2337699T3 (es) 2010-04-28
WO2005089454A3 (en) 2006-06-22
CN1938591A (zh) 2007-03-28
JP2007529752A (ja) 2007-10-25
AU2005223660B2 (en) 2011-06-23
IL177915A0 (en) 2006-12-31
MXPA06010659A (es) 2007-03-29
CN1938591B (zh) 2011-11-30
NZ549847A (en) 2009-08-28
WO2005089454A2 (en) 2005-09-29
AU2005223660A1 (en) 2005-09-29
EP1730526B1 (de) 2010-01-06
US20070154954A1 (en) 2007-07-05
EP1730526A2 (de) 2006-12-13
DE602005018751D1 (de) 2010-02-25
CA2559723C (en) 2010-02-23
EP1730526A4 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
EA200901646A1 (ru) Ингибиторы рецепторных тирозинкиназ и их применение
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
IL215027A (en) Anti-zb7r1 antibody, a formula containing it, and a method of increasing lymphocyte activity with its help
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
NO20083153L (no) Kjemiske forbindelser
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
EA200971077A1 (ru) Гетероциклические модуляторы киназы
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
EA200970113A1 (ru) Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties